Cargando…
Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19
BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is associated with complications and mortality in patients with coronavirus disease 2019 (COVID-19). However, there are no prognostic scores aimed to evaluate the risk of severe disease specifically in patients with MAFLD, despite its high...
Autores principales: | Macías-Rodríguez, Ricardo Ulises, Solís-Ortega, Alberto Adrián, Ornelas-Arroyo, Victoria J, Ruiz-Margáin, Astrid, González-Huezo, Maria Sarai, Urdiales-Morán, Nestor A, Román-Calleja, Berenice M, Mayorquín-Aguilar, Juan M, González-Regueiro, José A, Campos-Murguía, Alejandro, Toledo-Coronado, Israel Vicente, Chapa-Ibargüengoitia, Mónica, Valencia-Peña, Bernardo, Martínez-Cabrera, Carlos Fernando, Flores-García, Nayelli C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611707/ https://www.ncbi.nlm.nih.gov/pubmed/36312835 http://dx.doi.org/10.3748/wjg.v28.i37.5444 |
Ejemplares similares
-
Nutritional therapy for hepatocellular carcinoma
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021) -
Reply to: “Liver fibrosis and adverse outcomes in COVID-19”
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021) -
Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021) -
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021) -
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
por: Campos-Murguía, Alejandro, et al.
Publicado: (2020)